Blood Cancer Treatment Market By Type(Leukemia {Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML)} Lymphoma {Hodgkin Lymphoma, Non-Hodgkin Lymphoma (NHL)} Myeloma), By Treatment (Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, Stem Cell Transplantation, Supportive Care and Palliative Care), By Route of Administration (Oral, Intravenous (IV), Subcutaneous, Intramuscular, Others), By End-Users (Hospitals, Specialty Clinics, Homecare, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Industry Outlook

The Blood Cancer Treatment market accounted for USD 38.2 Billion in 2024 and is expected to reach USD 85.5 Billion by 2035, growing at a CAGR of around 7.6% between 2025 and 2035. Blood cancer treatment encompasses various medical therapies aimed at addressing cancers that affect the blood, bone marrow, and lymphatic systems, including leukemia, lymphoma, and multiple myeloma. Treatment options include chemotherapy, using drugs at their strongest levels to kill or constrain cancer cells; radiation therapy; and CAR-T cell therapy immunotherapy which stimulates the body's immune response. Targeted therapies directly target particular genetic mutations and stem cell transplants replace the bad, damaged marrow with healthy cells. Monoclonal antibodies also help the immune system to selectively identify and destroy the cancer cells. Any of these treatments mentioned are in any combination and tailored to a patient's specific condition, accompanied by ongoing assessment and supportive care.

Report Scope:

Market Dynamics

• Rising Cases of Leukemia, Lymphoma, and Myeloma Due to Environmental Factors and Genetic Influences

Blood cancers are increasingly on the rise, particularly leukemia, lymphoma, and myeloma, due to environmental and genetic factors. As estimated by the National Institutes of Health, or NIH, in 2020, there were approximately 474,519 new cases of leukemia worldwide. The highest incidence regions of cases were North America, Australia, New Zealand, and Western and Northern Europe. Epidemiologically, the incidence also varies with income, while presenting a 1.5 times higher incidence than that recorded in low-income countries.

The U.S. Environmental Protection Agency says two to six times a greater risk for leukemia has been reported among workers in industries that have high exposure to chemicals such as benzene. Radiation exposure, especially due to ionizing sources, is on the rise and WHO has reported an increased rate of leukemia among survivors of atomic bombs. Epidemiology also shows that other viruses like Epstein-Barr and HIV have a higher lymphoma rate. Genetic predispositions also count. People who have a family history of blood cancers raise the risk levels even more.

• Innovative Blood Cancer Therapies Driving Improved Patient Outcomes

The newest development in therapy concerning blood cancer, particularly CAR T-cell and next-generation sequencing that made a difference to the whole field, and as such, the latter has further enhanced treatment results. NCI recently announced that CAR T-cell therapy can reach remission rates of more than 80% majority of patients with relapsed or refractory acute lymphoblastic leukemia. Moreover, the FDA has approved many CAR T therapies, which enhance the overall survival rate.

New-generation sequencing enables precisely tailored therapies based on an individual's genetic makeup and proves far better than conventional treatments. Indeed, with a leap from only 14% in the 1970s, the American Cancer Society suggests that today, leukemia diagnosis has a five-year survival rate of nearly 63%. Again, in significant progress in the fight against blood cancers, The Leukemia & Lymphoma Society recently granted $5 million to Washington University School of Medicine to continue work developing novel immunotherapies for blood cancers. This development enhances not just the survival aspect but also the quality of patients' lives.

• The High Cost of Advanced Blood Cancer Treatments as a Barrier

The very expensive advanced blood cancer treatments, especially novel immunotherapies and stem cell transplants, are out of the reach of many patients and healthcare systems. According to a report by the American Cancer Society, the cost of CAR T-cell therapy can easily reach over $373,000 per patient, apart from all the added expenses of hospital and other supportive care. The National Cancer Institute has also reported that the cost of treating multiple myeloma may run anywhere from $75,000 to $250,000 per year based on the type of therapy.

As such, enormous costs weigh heavily on the health budgets, especially in regions with minimal coverage under insurance and where patients have no coverage. In this regard, many patients fall between a rock and a hard place since they must choose between desired therapy or not, thereby leading to the postponement of treatment or outright denial of needed therapy. This financial burden can exacerbate health inequities among low-income populations and make the accessibility of potentially lifesaving treatments even more challenging.

• Opportunities for Targeted Treatment Strategies Through Biomarker-Driven Therapy Development

The therapy development on particular biomarkers forms one of the excellent opportunities in the treatment of blood cancer using potentially more precise and effective approaches. Biomarkers enable clinicians to tailor therapies based on the unique genetic makeup of a patient's cancer, thus improving their effectiveness and offering the added advantage of avoiding the potentially damaging effects of unnecessary treatments. An example of this is the BCR-ABL gene that was identified in chronic myeloid leukemia (CML), therefore targeted therapy with imatinib (Gleevec) now has a 10-year survival rate of over 90% in patients at early stages, as cited by the American Society of Hematology.

The NCI estimates that a total of more than 200 cancer biomarkers have been found and identified, and many more are related to various blood cancers by 2022. This is an increasingly large database to draw upon for more accurate diagnostics and, consequently, treatment plans. Targeted therapies may also decrease healthcare costs: One study, published in the Journal of Managed Care & Specialty Pharmacy, estimated that they save up to 40% in total cancer care costs compared with traditional chemotherapy treatments. Biomarkers-based therapies have been and continue to be examined and invested in, to enhance the outcome for patients and provide the most potential benefits of targeted treatment.

• Increased Investment in Clinical Trials Unlocking New Treatment Possibilities for Blood Cancers

An increased investments in clinical trials play an important role in enhancing treatments of blood cancer. Clinical trials therefore become important in testing new drug combinations and treatment regimens that may be offered as much better alternatives to the patients. The National Cancer Institute estimated that about 20% of adult patients with cancer are treated with therapies as part of clinical trials, which simply marks the extent to which the results of therapeutic interventions could be improved through research. Funding of clinical trials has significantly risen over the past few years.

For instance, the United States' NIH spent more than $41 billion on biomedical research in 2021 alone, a huge portion of this amount was used on cancer. Combination therapy in a nutshell, is the best example of studying the way both older and newer immunotherapies work in conjunction with conventional chemotherapy. For instance, an article published in the Journal of Clinical Oncology reported that complete remission was up to 80% for the patients who suffered from chronic lymphocytic leukemia that were treated with the use of rituximab with venetoclax.

Industry Experts Opinion

“Meeting with hematologists in the field or at conferences, I feel their sense of urgency to find the next best medicine for their patients and their dedication to changing patients’ lives. It fuels our commitment to this area and makes me excited for the promise of our ongoing innovation to further build our legacy in advancing care for blood cancers and hematologic diseases. And I have absolutely no doubt that we can deliver even more transformative medicines for patients in the near future.”

• Victor Bultó, President of Innovative Medicines US

“Significant developments in hematology have meant patients’ expectations for treatment have fundamentally shifted. We're no longer just talking about extending lives, but about helping people with blood cancers and disorders live symptom-free and even potentially treatment-free, as part of our commitment to the next generation of innovation.”

• Jeff Legos, Executive Vice President, Global Head of Oncology and Hematology Development at Novartis

Segment Analysis

Based on the type of blood cancer, the market has been split into several key segments, such as leukemia, lymphoma, and myeloma are key major categories. Under leukemia, crucial subtypes include Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Chronic Myeloid Leukemia. The lymphoma segment essentially includes Hodgkin Lymphoma and Non-Hodgkin Lymphoma (NHL). Lastly, myeloma is a category unto itself. This classification emphasizes the heterogeneity of blood cancers and the need for treatment strategies directed at each particular type.

Based on treatment type, the market for blood cancer is divided into chemotherapy, radiation therapy, immunotherapy, targeted therapy, stem cell transplantation, and supportive or palliative care. Chemotherapy and radiation attack the cancer cells. Immunotherapy works on the boosting of the immune response. Targeted therapy works against specific traits of cancer and stem cell transplantation involves replacing the damaged bone marrow. Supportive and palliative care seeks to improve quality of life with symptom management. This variety itself speaks of the complexity of blood cancers and the requirement for personalized treatment approaches for them.

Regional Analysis

The North American market for blood cancer treatment offers better healthcare infrastructure and aggressive research activities, mainly in the field of regenerative medicine treatments for leukemia. Higher awareness amongst patients regarding personalized medicine helps improve their success rates during treatment, and the overall epidemiology of blood cancers continues to rise. In 2022, nearly 1,629,474 people in the U.S. were either in remission or under treatment for leukemia, lymphoma, myeloma, MDS, or MPNs. It is estimated that the aging population has an impact on market growth as people in old age are more prone to these conditions.

More recently, technology has been integrated into treatment protocols through telemedicine and digital health solutions aimed at increasing access to care from afar. Indeed, collaborations between academia and pharmaceutical firms have accelerated the rate of drug development innovation. Overall, North America is the hub of immense advancements in the treatment of blood cancer. The focus is placed on various improvements concerning the development and outcome along with the quality of life of the patients suffering from this disease.

Asia-Pacific is gaining speed in this rapidly developing market for blood cancer treatment due to the rising incidences of blood cancers and the increasing awareness of advanced treatment options. The aggregate growth of countries like China, India, and Japan has brought about substantial healthcare infrastructure development and research initiatives. There is a surge in the use of innovative therapies like immunotherapy and targeted treatments, among other diagnostic technological advancements. Most significant, Asia accounts for 5,809,431 deaths from cancer-a cause that necessitates highly effective drugs.

The unchecked rise and aging of the population only increase the demand to offer more therapies for blood cancer. Government policies to increase and deliver health services to more people at affordable rates are essential for this market to grow. Integrations between pharmaceutical businesses with local research organizations would boost innovation in and speed up the development of new therapies. In general, the Asia-Pacific market is beginning to emerge as a vibrant landscape for blood cancer treatment with increased dedication to enhancing patient outcomes and quality of care.

Competitive Landscape

The key players in the market of treating blood cancer include Roche, Novartis, Bristol-Myers Squibb, Amgen, and Gilead Sciences. Roche leads the segment, as it has a robust oncology drugs portfolio and is accelerating immunotherapy works with strategic collaborations. Novartis is the company that houses the CAR-T therapies under Kymriah for patients suffering from acute leukemia. The firm is also collaborating with biotech firms on combination treatments. Bristol-Myers Squibb continues to innovate since its acquisition of Celgene and is reviewing the development of clinical trials to increase patient outcomes. Amgen is working on multiple myeloma treatments with partnerships with the goal of improving drug delivery. Gilead Sciences also expands its market presence by acquiring Kite Pharma and also collaborating with research institutions to enrich its oncology pipeline. These key players push forward very significant developments in the treatment of blood cancers.

Blood Cancer Treatment Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In February 2024, AstraZeneca announced the successful completion of its acquisition of Gracell Biotechnologies Inc. (NASDAQ: GRCL), enhancing its focus on innovative cell therapies for cancer and autoimmune diseases.
• In October 24, 2023, the FDA approved Tibsovo (ivosidenib) for adults with relapsed or refractory myelodysplastic syndromes (MDS) with an IDH1 mutation, the first targeted therapy for this condition. The Abbott RealTime IDH1 Assay was also approved as a companion diagnostic.

Report Coverage:

By Type

• Leukemia
  • Acute Lymphoblastic Leukemia (ALL)
  • Acute Myeloid Leukemia (AML)
  • Chronic Lymphocytic Leukemia (CLL)
  • Chronic Myeloid Leukemia (CML)
• Lymphoma
  • Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma (NHL)
• Myeloma

By Treatment

• Chemotherapy
• Radiation Therapy
• Immunotherapy
• Targeted Therapy
• Stem Cell Transplantation
• Supportive Care and Palliative Care

By Route of Administration

• Oral
• Intravenous (IV)
• Subcutaneous
• Intramuscular
• Others

By End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Other

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Roche
• Novartis
• Bristol-Myers Squibb
• Amgen
• Gilead Sciences
• Celgene (Bristol-Myers Squibb)
• AbbVie
• Pfizer
• Merck & Co.
• Janssen Pharmaceuticals (Johnson & Johnson)
• Takeda Pharmaceutical Company
• AstraZeneca
• Incyte Corporation
• Regeneron Pharmaceuticals
• Bluebird Bio

Frequently Asked Questions (FAQs)